S&P 500 Falls 2.5% Amid Geopolitical Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Should l Buy EOLS?
S&P 500 succumbed to another day of heavy selling amid geopolitical concerns on Tuesday, falling as much as 2.5% at one point, as fears of a protracted Middle East conflict that drew in multiple regional players roiled sentiment. Stocks recovered from the opening hour lows however as traders bought the beaten down Software Application names while also hiding out in the safety of high-yielding Telecoms. The opening hour of the evening session is seeing a calmer mood with equity futures down by only a decimal, even though investors remain on high alert for another "tape bomb" in a headline-driven volatile macro environment.In commodities, Gold and Silver were down sharply, refusing to act as stores of refuge, with a second consecutive session of much stronger U.S. Dollar denting precious metals. WTI Crude Oil is flat in electronic trade in the wake of a large build in inventories reported by API, having retreated below $74.50 after rising as high as $78 per barrel earlier.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Evolusup 17.4%B&G Foodsup 7.7%Ross Storesup 6.1%Boxup 3.5%Cricutup 2.8%ALSO HIGHER -Modernaup 8.0% after announcing litigation settlementDOWN AFTER EARNINGS -WEBTOON Entertainmentdown 14.3%GitLabdown 8.9%STAAR Surgicaldown 8.9%QuickLogicdown 3.7%Crexendodown 2.3%Crowdstrikedown 0.7%
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.130
Low
18.00
Averages
19.25
High
20.00
Current: 4.130
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Shares Surge 36% After Exceeding Q4 2025 Earnings Expectations
- Strong Earnings Report: Evolus reported $90.3 million in revenue for Q4 2025, exceeding market expectations by $0.7 million and reflecting approximately 14% year-over-year growth, driven by increased sales of its anti-wrinkle product Jeuveau, indicating a significant improvement in overall performance.
- First Profit in Years: The company achieved a net income of $130,000 for the first time in nearly five years, compared to a net loss of $6.7 million in the same period last year, marking a substantial turnaround in its financial health and boosting investor confidence.
- Slight Margin Decline: Despite achieving profitability, gross margin slipped to 65.7% from 66.7% a year ago, indicating rising cost pressures that could impact future profitability.
- Positive Future Outlook: Evolus projects net revenue between $327 million and $337 million for 2026, suggesting a year-over-year growth rate of 10% to 13%, with total net revenue expected to reach $450 million to $500 million by 2028, reflecting a three-year CAGR of 15% to 19%.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
See More
Evolus Q4 2025 Earnings Call Insights
- Revenue Growth: Evolus reported global net revenue of $90.3 million for Q4 2025, with Jeuveau contributing $83.1 million and Evolysse $7.2 million, leading to a full-year revenue of $297.2 million, reflecting a 12% increase and indicating the company's resilience in a challenging market.
- International Expansion: The company now operates in nine countries outside the U.S., with international revenue nearly doubling year-over-year, which is expected to further drive revenue growth, particularly in expanding markets like Europe and Australia.
- Profitability Outlook: The CFO provided guidance for 2026 revenue between $327 million and $337 million, with gross margins expected between 65.5% and 67%, showcasing effective cost management and resource allocation that positions the company for sustainable profitability.
- New Product Launches: Evolus plans to introduce Estyme in Europe in Q2 2026 and anticipates FDA approval for Evolysse Sculpt in Q4 2026, which will enhance its product portfolio and drive market share growth.
See More
Evolus Shares Surge 36% After Exceeding Q4 2025 Earnings Expectations
- Strong Earnings Report: Evolus reported $90.3 million in revenue for Q4 2025, exceeding market expectations by $0.7 million and reflecting approximately 14% year-over-year growth, driven by increased sales of its anti-wrinkle product Jeuveau, indicating a significant improvement in overall performance.
- First Profit in Years: The company achieved a net income of $130,000 for the first time in nearly five years, compared to a net loss of $6.7 million in the same period last year, marking a substantial turnaround in its financial health and boosting investor confidence.
- Slight Margin Decline: Despite achieving profitability, gross margin slipped to 65.7% from 66.7% a year ago, indicating rising cost pressures that could impact future profitability.
- Positive Future Outlook: Evolus projects net revenue between $327 million and $337 million for 2026, suggesting a year-over-year growth rate of 10% to 13%, with total net revenue expected to reach $450 million to $500 million by 2028, reflecting a three-year CAGR of 15% to 19%.
See More
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
- Quarterly Highlights: Evolus reported a Q4 GAAP EPS of $0.00, beating expectations by $0.05, while revenue of $90.3 million, despite a 14.4% year-over-year increase, fell short of estimates by $0.38 million, indicating revenue growth challenges.
- 2026 Revenue Projections: The company anticipates total net revenues for 2026 to range between $327 million and $337 million, representing a 10% to 13% growth over the previous year, reflecting cautious optimism for future growth.
- Gross Margin and Operating Expenses: Evolus expects an adjusted gross profit margin of 65.5% to 67.0% for 2026, with non-GAAP operating expenses estimated between $210 million and $216 million, demonstrating the company's efforts to maintain profitability amid operational efficiency.
- Long-term Financial Outlook: The long-term outlook for 2028 indicates total net revenues between $450 million and $500 million, with a three-year CAGR of 15% to 19% and adjusted EBITDA margins of 13% to 15%, showcasing the company's confidence in future growth.
See More
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
- Earnings Announcement Schedule: Evolus is set to release its Q4 earnings report on March 3rd after market close, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.04, reflecting a substantial year-over-year increase of 136.4%, indicating a notable improvement in the company's profitability.
- Revenue Forecast Fluctuations: Evolus anticipates Q4 net revenue between $88.6 million and $90.6 million, representing a 13.5% year-over-year growth; however, the revenue estimates have faced six downward revisions in the past three months, raising concerns about its growth outlook.
- Estimate Revision Trends: Over the last three months, there have been no upward revisions to Evolus's EPS estimates, with one downward revision, highlighting analysts' cautious stance on the company's future performance.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
See More
